한글목차

세계의 인슐린 글라진 시장은 2025년에 58억 1,000만 달러로 추정되며, 2032년에는 90억 9,000만 달러에 달할 것으로 예측되며, 2025-2032년 연간 평균 성장률(CAGR)은 6.6%로 성장할 것으로 예측됩니다.

도표. 인슐린 글라진 시장 점유율(%), 2025년 지역별

Lantus라고도 알려진 인슐린 글라진(Insulin Glargine)은 당뇨병 치료에 사용되는 지속형 기초 인슐린입니다. 이는 재조합 DNA 기술로 만들어진 인간 인슐린의 합성 형태로 산성 환경에 용해되도록 설계되어 있습니다. 주사하면 피하 조직에 침전되어 미세 결정체를 형성하고, 이 결정체에서 인슐린이 점차적으로 혈액에 흡수되는 저장소를 형성합니다. 이러한 서방형 및 작용 시간 프로파일로 인해 1일 1회 투여로 24시간 동안 제 1형 및 2형 당뇨병 환자의 혈당을 조절할 수 있습니다. 인슐린 데테밀이나 인슐린 NPH와 같은 다른 기초 인슐린 제제에 비해 인슐린글라진은 흡수 프로파일이 완만하여 혈중 인슐린 농도를 원활하고 일정하게 유지할 수 있습니다.

시장 역학

세계의 인슐린 글라진 시장 성장은 전 세계 당뇨병 유병률 증가가 주도하고 있습니다. 국제당뇨병연맹(International Diabetes Federation 2021)의 추정에 따르면 2021년에는 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있으며, 2030년에는 6억 4,300만 명, 2045년에는 7억 8,300만 명으로 증가할 것으로 예상됩니다. 당뇨병은 노년층에서 더 흔하므로 노인 인구 증가도 시장 성장에 기여하고 있습니다. 그러나 특히 개발도상국에서는 비용의 제약이 제약 요인으로 작용하고 있습니다. 긍정적인 측면은 보다 효과적이고 편리한 약물전달 기술의 개발이 진행되고 있으며, 새로운 비즈니스 기회를 기대할 수 있다는 점입니다.

본 조사의 주요 특징

• 세계의 인슐린 글라진(인슐린 글라진) 시장에 대해 조사 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
• 또한 다양한 부문에 걸친 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
• 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계의 인슐린 글라진 시장의 주요 기업 개요을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 보입니다.
• 세계의 인슐린 글라진 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 인슐린 글라진 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사의 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 리포트 설명
  • 시장의 정의와 범위
• 개요
• COM(Coherent Opportunity Map)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 전 세계에서 당뇨병의 이환율 증가
  • 인슐린 글라진의 고비용
  • 당뇨병 관리에 관한 의식의 향상
• 영향 분석
• 규제 시나리오
• 제품 발매/승인
• PEST 분석
• Porter의 산업 분석
• 합병과 인수 시나리오

제4장 세계의 인슐린 글라진 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• COVID-19 역학
• 공급측과 수요측 분석
• 경제에 대한 영향

제5장 세계의 인슐린 글라진 시장, 유형별, 2020-2032년(10억 달러)

• 서론
• Lantus
• Basaglar
• Toujeo
• Soliqua/Suliqua
• 기타

제6장 세계의 인슐린 글라진 시장, 당뇨병 유형별, 2020-2032년(10억 달러)

• 서론
• 2형 당뇨병
• 1형 당뇨병

제7장 세계의 인슐린 글라진 시장, 유통 채널별, 2020-2032년(10억 달러)

• 서론
• 병원 약국
• 소매 약국
• 온라인 약국

제8장 세계의 인슐린 글라진 시장, 지역별, 2020-2032년(10억 달러)

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제9장 경쟁 구도

• Sanofi
• Biocon
• Eli Lilly and Company
• Boehringer Ingelheim
• Gan & Lee
• Kalbe Pharma
• Polus Biopharm
• Samsung Bioepis
• Wockhardt
• Novo Nordisk AS
• Julphar
• Viatris Inc.

제10장 애널리스트의 시점

• 운명의 수레바퀴
• COM(Coherent Opportunity Map)

제11장 참고 문헌과 조사 방법

• 참고 문헌
• 조사 방법

영문목차

Global Insulin Glargine Market is estimated to be valued at USD 5.81 Bn in 2025 and is expected to reach USD 9.09 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032.

Figure. Insulin Glargine Market Share (%), By Region 2025

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

• This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

• Type:
  • Lantus
  • Basaglar
  • Toujeo
  • Soliqua/Suliqua
  • Others
• Diabetes Type:
  • Type 2 Diabetes
  • Type 1 Diabetes
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Sanofi
  • Biocon
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Gan & Lee
  • Kalbe Pharma
  • Polus Biopharm
  • Samsung Bioepis
  • Wockhardt
  • Novo Nordisk AS
  • Julphar
  • Viatris Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Diabetes Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of diabetes worldwide
  • High cost of insulin glargine
  • Increase in awareness about diabetes management
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Insulin Glargine Market, By Type, 2020-2032, (USD BN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Lantus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Basaglar
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Toujeo
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Soliqua/Suliqua
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2020-2032, (USD BN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Type 2 Diabetes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Type 1 Diabetes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2020-2032, (USD BN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)

8. Global Insulin Glargine Market, By Region, 2020-2032, (USD BN)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• North America
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD BN)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD BN)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD BN)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biocon
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gan & Lee
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kalbe Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Polus Biopharm
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Samsung Bioepis
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Wockhardt
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novo Nordisk AS
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Julphar
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact